Adjuvant Interleukin2 (Proleukin)and 5-(3,3 Dimethyl-1-Triazeno) Imidazole-4-Carboxamide (DTIC) in Resected High-Risk Primary and Regionally Metastatic Melanoma.

Trial Profile

Adjuvant Interleukin2 (Proleukin)and 5-(3,3 Dimethyl-1-Triazeno) Imidazole-4-Carboxamide (DTIC) in Resected High-Risk Primary and Regionally Metastatic Melanoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Dacarbazine (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms DTIC
  • Most Recent Events

    • 03 Nov 2017 Planned End Date changed from 1 Aug 2020 to 1 Aug 2022.
    • 03 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2022.
    • 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top